{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:17:31Z","timestamp":1773976651041,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Health and Family planing Commission of Chengdu","award":["2015080"],"award-info":[{"award-number":["2015080"]}]},{"name":"Youth Innovation Research Fund of Sichuan Medicine","award":["Q14004"],"award-info":[{"award-number":["Q14004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12880-017-0184-x","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T22:03:31Z","timestamp":1485900211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiang-ke","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susant Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"184_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277\u2013300.","journal-title":"CA Cancer J Clin"},{"key":"184_CR2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","volume":"366","author":"FH Schr\u00f6der","year":"2012","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11\u00a0years of follow-up. N Engl J Med. 2012;366:981\u201390.","journal-title":"N Engl J Med"},{"key":"184_CR3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","volume":"94","author":"R Etzioni","year":"2002","unstructured":"Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981\u201390.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"184_CR4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jnci\/djp001","volume":"101","author":"G Draisma","year":"2009","unstructured":"Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"184_CR5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.294.1.66","volume":"294","author":"IM Thompson","year":"2005","unstructured":"Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0\u00a0ng\/ml or lower. JAMA. 2005;294:66\u201370.","journal-title":"JAMA"},{"key":"184_CR6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2008.18.1685","volume":"27","author":"AJ Vickers","year":"2009","unstructured":"Vickers AJ, Savage C, O\u2019Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27:398\u2013403.","journal-title":"J Clin Oncol"},{"key":"184_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ucl.2015.08.004","volume":"43","author":"ML McDonald","year":"2016","unstructured":"McDonald ML, Parsons JK. 4-Kallikrein test and Kallikrein markers in prostate cancer screening. Urol Clin North Am. 2016;43:39\u201346.","journal-title":"Urol Clin North Am"},{"key":"184_CR8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Neste Van","year":"2016","unstructured":"Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70:740\u20138.","journal-title":"Eur Urol"},{"key":"184_CR9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00345-014-1370-x","volume":"33","author":"D Junker","year":"2015","unstructured":"Junker D, Quentin M, Nagele U, et al. Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis. World J Urol. 2015;33:1023\u201330.","journal-title":"World J Urol"},{"key":"184_CR10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1148\/radiol.16151133","volume":"280","author":"SY Park","year":"2016","unstructured":"Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology. 2016;280:108\u201316.","journal-title":"Radiology"},{"key":"184_CR11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2214\/AJR.13.10591","volume":"201","author":"I Karademir","year":"2013","unstructured":"Karademir I, Shen D, Peng Y, et al. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013;201:1041\u20138.","journal-title":"AJR Am J Roentgenol"},{"key":"184_CR12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1109\/TMI.2012.2230018","volume":"32","author":"S Liao","year":"2013","unstructured":"Liao S, Gao Y, Lian J, Shen D. Sparse patch-based label propagation for accurate prostate localization in CT images. IEEE Trans Med Imaging. 2013;32:419\u201334.","journal-title":"IEEE Trans Med Imaging"},{"key":"184_CR13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.crad.2015.06.093","volume":"70","author":"T Barrett","year":"2015","unstructured":"Barrett T, Turkbey B, Choyke PL. PI-RADS version 2: what you need to know. Clin Radiol. 2015;70:1165\u201376.","journal-title":"Clin Radiol"},{"key":"184_CR14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1148\/radiol.13121501","volume":"268","author":"P Puech","year":"2013","unstructured":"Puech P, Rouvi\u00e8re O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology. 2013;268:461\u20139.","journal-title":"Radiology"},{"key":"184_CR15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mri.2013.02.007","volume":"31","author":"DN Costa","year":"2013","unstructured":"Costa DN, Bloch BN, Yao DF, et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. Magn Reson Imaging. 2013;31:947\u201352.","journal-title":"Magn Reson Imaging"},{"key":"184_CR16","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-10-1328","volume":"16","author":"AJ Vickers","year":"2010","unstructured":"Vickers AJ, Cronin AM, Roobol MJ, et al. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010;16:4374\u201381.","journal-title":"Clin Cancer Res"},{"key":"184_CR17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOU.0b013e328329a2ed","volume":"19","author":"A Villers","year":"2009","unstructured":"Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol. 2009;19:274\u201382.","journal-title":"Curr Opin Urol"},{"key":"184_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eururo.2015.08.038","volume":"69","author":"JO Barentsz","year":"2016","unstructured":"Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol. 2016;69:41\u20139.","journal-title":"Eur Urol"},{"key":"184_CR19","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1007\/s00330-016-4230-9","volume":"26","author":"S Woo","year":"2016","unstructured":"Woo S, Kim SY, Lee J, Kim SH, Cho JY. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3\u2009+\u20094) prostate cancer. Eur Radiol. 2016;26:3580\u20137.","journal-title":"Eur Radiol"},{"key":"184_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2214\/AJR.13.11046","volume":"202","author":"M Rooij de","year":"2014","unstructured":"de Rooij M, Hamoen EH, F\u00fctterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202:343\u201351.","journal-title":"AJR Am J Roentgenol"},{"key":"184_CR21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy na\u00efve patients. BJU Int. 2017;119:225\u201333.","journal-title":"BJU Int"},{"key":"184_CR22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0090-4295(01)01515-1","volume":"59","author":"B Tombal","year":"2002","unstructured":"Tombal B, Querton M, de Nayer P, et al. Free\/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology. 2002;59:256\u201360.","journal-title":"Urology"},{"key":"184_CR23","first-page":"661","volume":"95","author":"A Saema","year":"2012","unstructured":"Saema A, Kochakarn W, Lertsithichai P. PSA density and prostate cancer detection. J Med Assoc Thai. 2012;95:661\u20136.","journal-title":"J Med Assoc Thai"},{"key":"184_CR24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00432-008-0400-8","volume":"134","author":"XY Zheng","year":"2008","unstructured":"Zheng XY, Xie LP, Wang YY, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4\u201310\u00a0ng\/mL. J Cancer Res Clin Oncol. 2008;134:1207\u201310.","journal-title":"J Cancer Res Clin Oncol"},{"key":"184_CR25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000100836","volume":"78","author":"JS Lee","year":"2007","unstructured":"Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int. 2007;78:323\u20137.","journal-title":"Urol Int"},{"key":"184_CR26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000144057","volume":"81","author":"CW Jeong","year":"2008","unstructured":"Jeong CW, Park HK, Hong SK, Byun SS, Lee HJ, Lee SE. Comparison of prostate volume measured by transrectal ultrasonography and MRI with the actual prostate volume measured after radical prostatectomy. Urol Int. 2008;81:179\u201385.","journal-title":"Urol Int"},{"key":"184_CR27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1515\/cclm-2015-0599","volume":"54","author":"RJ Hendriks","year":"2016","unstructured":"Hendriks RJ, Dijkstra S, Jannink SA, et al. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clin Chem Lab Med. 2016;54:483\u201392.","journal-title":"Clin Chem Lab Med"},{"key":"184_CR28","first-page":"596797","volume":"2015","author":"D Fang","year":"2015","unstructured":"Fang D, Ren D, Zhao C, et al. Prevalence and risk factors of prostate cancer in Chinese Men with PSA 4\u201310\u00a0ng\/mL Who underwent TRUS-guided prostate biopsy: the utilization of PAMD score. Biomed Res Int. 2015;2015:596797.","journal-title":"Biomed Res Int"},{"key":"184_CR29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.juro.2009.10.046","volume":"183","author":"JI Epstein","year":"2010","unstructured":"Epstein JI. An update of the Gleason grading system. J Urol. 2010;183:433\u201340.","journal-title":"J Urol"},{"key":"184_CR30","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","volume":"293","author":"PC Albertsen","year":"2005","unstructured":"Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095\u2013101.","journal-title":"JAMA"},{"key":"184_CR31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1148\/radiol.12112374","volume":"265","author":"GJ Litjens","year":"2012","unstructured":"Litjens GJ, Hambrock T, Hulsbergen-van de Kaa C, Barentsz JO, Huisman HJ. Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology. 2012;265:260\u20136.","journal-title":"Radiology"},{"key":"184_CR32","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-07-4713","volume":"14","author":"SF Shariat","year":"2008","unstructured":"Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res. 2008;14:4400\u20137.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-017-0184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T05:28:54Z","timestamp":1498368534000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-017-0184-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1186\/s12880-017-0184-x","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,1]]},"article-number":"11"}}